The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study
Background. Several health care services are required to get eligibility to PCSK9-inhibitors medicines and the follow-up of patients being treated. The ultimate goal is making prescriptions appropriate and monitoring the effects of these drugs. Some recent papers (opinion / consensus documents) hig...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2022-07-01
|
| Series: | Global & Regional Health Technology Assessment |
| Subjects: | |
| Online Access: | https://journals.aboutscience.eu/index.php/grhta/article/view/2415 |
| _version_ | 1811293248438665216 |
|---|---|
| author | Arianna Bertolani Roberto Ravasio Paola Raimondo Claudio Jommi |
| author_facet | Arianna Bertolani Roberto Ravasio Paola Raimondo Claudio Jommi |
| author_sort | Arianna Bertolani |
| collection | DOAJ |
| description |
Background. Several health care services are required to get eligibility to PCSK9-inhibitors medicines and the follow-up of patients being treated. The ultimate goal is making prescriptions appropriate and monitoring the effects of these drugs. Some recent papers (opinion / consensus documents) highlighted the necessity to make simpler this clinical pathway. Our paper illustrates the cost of this pathway incurred by patients (direct healthcare and non-healthcare costs, productivity losses by patients and their possible care-giver due to the time dedicated to healthcare services).
Methods. The study relied on a retrospective data collection through a structured questionnaire administered to 240 patients, being on treatments with PCSK9-inhibiotrd drugs for at least one year. Patients were recruited in 4 Italian healthcare centres from June 2020 to July 2021.
Results. Recruited patients are 64 years old on average. 64% of patients are males and 36% are actively employed and working. Mean cost incurred by patients amounts to € 926,1. Direct healthcare costs, direct non-healthcare costs and productivity losses equal to € 463,5 (50%), € 136,7 (15%) and € 325,9 (35%) respectively. Healthcare services fully covered by the National Health Service account for 56% of the total. Co-payments are applied to 26% of healthcare services, whereas patients pay the full price for 18% healthcare services.
Discussion. Getting eligibility to PCSK9-inhibitors and managing patients’ follow-up generate important costs incurred by patients. Furthermore, these costs are very different across healthcare centres. We are fully aware that appropriateness of prescriptions and patients’ follow-up are very important. However, simplifying the clinical pathway would bring economic advantages and could make more homogenous the way this pathway is managed by healthcare centres.
|
| first_indexed | 2024-04-13T04:57:41Z |
| format | Article |
| id | doaj.art-138fe890f28a4768a3bd0b670edde512 |
| institution | Directory Open Access Journal |
| issn | 2284-2403 2283-5733 |
| language | English |
| last_indexed | 2024-04-13T04:57:41Z |
| publishDate | 2022-07-01 |
| publisher | AboutScience Srl |
| record_format | Article |
| series | Global & Regional Health Technology Assessment |
| spelling | doaj.art-138fe890f28a4768a3bd0b670edde5122022-12-22T03:01:25ZengAboutScience SrlGlobal & Regional Health Technology Assessment2284-24032283-57332022-07-019110.33393/grhta.2022.2415The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR StudyArianna Bertolani0Roberto Ravasio1Paola Raimondo2Claudio Jommi3CERGAS (Centre for Research on Health and Social Care Management), SDA Bocconi School of Management, Università Bocconi, Milan - ItalyMA Provider, Milan - ItalyMA Provider, Milan - ItalyCERGAS (Centre for Research on Health and Social Care Management), SDA Bocconi School of Management, Università Bocconi, Milan - Italy Background. Several health care services are required to get eligibility to PCSK9-inhibitors medicines and the follow-up of patients being treated. The ultimate goal is making prescriptions appropriate and monitoring the effects of these drugs. Some recent papers (opinion / consensus documents) highlighted the necessity to make simpler this clinical pathway. Our paper illustrates the cost of this pathway incurred by patients (direct healthcare and non-healthcare costs, productivity losses by patients and their possible care-giver due to the time dedicated to healthcare services). Methods. The study relied on a retrospective data collection through a structured questionnaire administered to 240 patients, being on treatments with PCSK9-inhibiotrd drugs for at least one year. Patients were recruited in 4 Italian healthcare centres from June 2020 to July 2021. Results. Recruited patients are 64 years old on average. 64% of patients are males and 36% are actively employed and working. Mean cost incurred by patients amounts to € 926,1. Direct healthcare costs, direct non-healthcare costs and productivity losses equal to € 463,5 (50%), € 136,7 (15%) and € 325,9 (35%) respectively. Healthcare services fully covered by the National Health Service account for 56% of the total. Co-payments are applied to 26% of healthcare services, whereas patients pay the full price for 18% healthcare services. Discussion. Getting eligibility to PCSK9-inhibitors and managing patients’ follow-up generate important costs incurred by patients. Furthermore, these costs are very different across healthcare centres. We are fully aware that appropriateness of prescriptions and patients’ follow-up are very important. However, simplifying the clinical pathway would bring economic advantages and could make more homogenous the way this pathway is managed by healthcare centres. https://journals.aboutscience.eu/index.php/grhta/article/view/2415Clinical pathwayCostsEligibilityFollow-upOrganisational impactPCSK9 |
| spellingShingle | Arianna Bertolani Roberto Ravasio Paola Raimondo Claudio Jommi The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study Global & Regional Health Technology Assessment Clinical pathway Costs Eligibility Follow-up Organisational impact PCSK9 |
| title | The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study |
| title_full | The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study |
| title_fullStr | The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study |
| title_full_unstemmed | The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study |
| title_short | The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study |
| title_sort | costs incurred by patients to get eligibility to pcsk9 treatment and one year follow up the results of the prior study |
| topic | Clinical pathway Costs Eligibility Follow-up Organisational impact PCSK9 |
| url | https://journals.aboutscience.eu/index.php/grhta/article/view/2415 |
| work_keys_str_mv | AT ariannabertolani thecostsincurredbypatientstogeteligibilitytopcsk9treatmentandoneyearfollowuptheresultsofthepriorstudy AT robertoravasio thecostsincurredbypatientstogeteligibilitytopcsk9treatmentandoneyearfollowuptheresultsofthepriorstudy AT paolaraimondo thecostsincurredbypatientstogeteligibilitytopcsk9treatmentandoneyearfollowuptheresultsofthepriorstudy AT claudiojommi thecostsincurredbypatientstogeteligibilitytopcsk9treatmentandoneyearfollowuptheresultsofthepriorstudy AT ariannabertolani costsincurredbypatientstogeteligibilitytopcsk9treatmentandoneyearfollowuptheresultsofthepriorstudy AT robertoravasio costsincurredbypatientstogeteligibilitytopcsk9treatmentandoneyearfollowuptheresultsofthepriorstudy AT paolaraimondo costsincurredbypatientstogeteligibilitytopcsk9treatmentandoneyearfollowuptheresultsofthepriorstudy AT claudiojommi costsincurredbypatientstogeteligibilitytopcsk9treatmentandoneyearfollowuptheresultsofthepriorstudy |